Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) for TAZVERIK (tazemetostat) tablet, 200 milligrams (mg), held by Epizyme, Inc., an Ipsen Company...
Want the full context? Use Regulator to track the source, deadlines, and weekly briefing.Document type: Notice. Agency: Health and Human Services Department, Food and Drug Administration. Published: 2026-06-22.
Why this matters to food and beverage teams
This notice is worth screening if your team tracks health and human services department, food and drug administration activity that could affect ingredients, labeling, plant operations, imports, or compliance timing.
Federal Register items are often early signals. Even when they look procedural, they can affect comment windows, effective dates, or how suppliers and plants plan around upcoming changes.
Turn this source item into a compliance workflow
Get weekly F&B regulatory briefings, deadline tracking, and beta access to the searchable Regulator workspace.